Arnaud François
Arnaud François has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Curie
Internal Medicine department, Rouen University Hospital Center, 1, rue de Germont, 76031 Rouen, France
1 shared publication - Aude Di Fiore
Department of Hepatology and Gastroenterology, Rouen University Hospital, 1 Rue de Germont, 76031 Rouen, France
1 shared publication - Baptiste Dilly
Nephrology department, Rouen University Hospital, 147 avenue du Maréchal Juin 76230 Bois Guillaume, Rouen, France
1 shared publication - Charlotte Laurent
Department of Nephrology, Transplantation and Hemodialysis, Rouen University Hospital, 76000 Rouen, France
1 shared publication - Dominique Bertrand
CHU Rouen Nephrology Department Rouen
1 shared publication - Dominique Guerrot
Department of Nephrology, Transplantation and Hemodialysis, Rouen University Hospital, Rouen, France
1 shared publication
Latest Publications
- Open Access
- 11 October 2019
- Published by Springer Nature in BMC Nephrology
- Vol. 20 (1) , 1-5
Ipilimumab-induced renal granulomatous arteritis: a case report
Background: Immune Checkpoint Inhibitors (ICPIs) are promising new drugs in treatment of advanced tumours targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein-1 (PD1) or its ligand (PDL-1). Ipilimumab is a monoclonal antibody targeting the CTLA-4 receptor used in treatment of metastatic melanoma. By increasing activity of the immune system, ICPIs lead to immune-related adverse events, such as dermatitis, colitis or hepatitis. ICPIs-related kidney adverse events are rare and acute tubulointerstitial nephritis with or without granuloma have mainly been reported. Case presentation: We report a case of acute kidney injury in a patient with melanoma treated by ipilimumab. Kidney biopsy revealed acute interlobular and juxtaglomerular granulomatous arteritis, which has not yet been reported in patients treated by ICPIs. Kidney function partially recovered after ipilimumab discontinuation and oral prednisone. Unfortunately, the patient died a few months later from progression of his melanoma. Conclusion: This case highlights a new mechanism of acute kidney injury related to ICPIs and supports the interest of kidney biopsy in case of ICPIs related acute renal failure.
- 11 October 2019
- Published by Springer Nature in BMC Nephrology
- Vol. 20 (1) , 1-5
Open AccessIpilimumab-induced renal granulomatous arteritis: a case report
Background: Immune Checkpoint Inhibitors (ICPIs) are promising new drugs in treatment of advanced tumours targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein-1 (PD1) or its ligand (PDL-1). Ipilimumab is a monoclonal antibody targeting the CTLA-4 receptor used in treatment of metastatic melanoma. By increasing activity of the immune system, ICPIs lead to immune-related adverse events, such as dermatitis, colitis or hepatitis. ICPIs-related kidney adverse events are rare and acute tubulointerstitial nephritis with or without granuloma have mainly been reported. Case presentation: We report a case of acute kidney injury in a patient with melanoma treated by ipilimumab. Kidney biopsy revealed acute interlobular and juxtaglomerular granulomatous arteritis, which has not yet been reported in patients treated by ICPIs. Kidney function partially recovered after ipilimumab discontinuation and oral prednisone. Unfortunately, the patient died a few months later from progression of his melanoma. Conclusion: This case highlights a new mechanism of acute kidney injury related to ICPIs and supports the interest of kidney biopsy in case of ICPIs related acute renal failure.
- Open Access
- 2 August 2013
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 11 (1) , 171
Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib
Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma (HCC) in Child-Pugh A patients. We describe the case of a patient who presented with a large HCC in the left liver associated with portal vein thrombosis (PVT). After 9 months of sorafenib treatment, reassessment showed that the tumors had decreased in size with recanalization of the portal vein. A lateral left hepatectomy was performed and pathology showed complete necrosis of the tumor. Sorafenib can downstage HCC in patients with cirrhosis allowing further surgical resection.
- 2 August 2013
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 11 (1) , 171
Open AccessComplete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib
Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma (HCC) in Child-Pugh A patients. We describe the case of a patient who presented with a large HCC in the left liver associated with portal vein thrombosis (PVT). After 9 months of sorafenib treatment, reassessment showed that the tumors had decreased in size with recanalization of the portal vein. A lateral left hepatectomy was performed and pathology showed complete necrosis of the tumor. Sorafenib can downstage HCC in patients with cirrhosis allowing further surgical resection.